QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
Thirty years ago, at age 64, through PSA testing, Eugene (Gene) Golub received a diagnosis of prostate cancer. He consulted Dr. Catalona, who then worked at Washington University in St. Louis and successfully treated him. Years later, they reconnected at…
Multiparametric Magnetic Resonance Imaging (mpMRI) improves the pathway for diagnosing prostate cancer and detecting the clinically significant form of this disease. Moreover, some with a negative MRI scan can avoid prostate biopsy. In routine clinical practice, the PI-RADS scoring system…
SEER Cancer, the authoritative source for cancer statistics in the US, estimates that about 7 out of 8 men will never be diagnosed with prostate cancer during their lifetime, and nearly 90% who receive the diagnosis never suffer or die…
The goal of PSA screening is to test asymptomatic men and improve health outcomes by diagnosing the cancer at an early stage. A benefit of screening is to decrease the proportion of advanced-stage cases at the time of diagnosis and…
Researchers develop artificial intelligence (AI) algorithms via machine learning analysis of scanned biopsy slide images. They can identify patterns associated with prostate cancer in its various microscopic patterns. These algorithms are trained progressively based on classifying cases and controls regarding…
Dr. Catalona and his collaborators studied the associations between the patient’s germline genomic polygenic risk score (PRS) and prostate cancer tumor upgrading and tumor features in men enrolled in an active surveillance program.1 They used the new PRS consisting of…
There has been a long debate about whether drinking alcohol increases the risk of prostate cancer (PCa). Some studies show that drinking, especially in large amounts, is linked to higher chances of developing PCa, while others have suggested that wine…
The TheraP study compared two treatments, (1) lutetium-177 [177Lu]Lu-PSMA-617 and (2) a chemotherapy agent, cabazitaxel, for men with metastatic castration-resistant prostate cancer that had worsened after chemotherapy with docetaxel. This phase 2 trial, conducted at 11 centers in Australia, focused…
QUEST has personal interest stories describing scientific discoveries, highlighting their development into excellent new treatments, sometimes for different diseases. These stories give hope to all of us, and often, one discovery serves as the foundation for another. While Dr. Catalona’s…
Prostate cancer is one of the leading causes of cancer death in men. To screen for it, doctors often use a blood test to measure PSA levels. PSA is an enzyme produced by the prostate gland, and higher levels can…
"*" indicates required fields
